Patterson AV - Search Results

1

Targeting gene expression to hypoxic tumor cells.

Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ, Harris AL. Dachs GU, et al. Among authors: patterson av. Nat Med. 1997 May;3(5):515-20. doi: 10.1038/nm0597-515. Nat Med. 1997. PMID: 9142119

2

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, Stratford IJ. Patterson AV, et al. Br J Cancer. 1995 Nov;72(5):1144-50. doi: 10.1038/bjc.1995.478. Br J Cancer. 1995. PMID: 7577460 Free PMC article.

3

Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.

Patterson AV, Zhang H, Moghaddam A, Bicknell R, Talbot DC, Stratford IJ, Harris AL. Patterson AV, et al. Br J Cancer. 1995 Sep;72(3):669-75. doi: 10.1038/bjc.1995.392. Br J Cancer. 1995. PMID: 7669579 Free PMC article.

4

The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).

Patterson AV, Robertson N, Houlbrook S, Stephens MA, Adams GE, Harris AL, Stratford IJ, Carmichael J. Patterson AV, et al. Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):369-72. doi: 10.1016/0360-3016(94)90291-7. Int J Radiat Oncol Biol Phys. 1994. PMID: 8195035

5

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, Strafford IJ. Patterson AV, et al. Br J Cancer. 1997;76(10):1338-47. doi: 10.1038/bjc.1997.558. Br J Cancer. 1997. PMID: 9374381 Free PMC article.

6

Thymidine phosphorylase moderates thymidine-dependent rescue after exposure to the thymidylate synthase inhibitor ZD1694 (Tomudex) in vitro.

Patterson AV, Talbot DC, Stratford IJ, Harris AL. Patterson AV, et al. Cancer Res. 1998 Jul 1;58(13):2737-40. Cancer Res. 1998. PMID: 9661884

7

Enzymology of tirapazamine metabolism: a review.

Patterson AV, Saunders MP, Chinje EC, Patterson LH, Stratford IJ. Patterson AV, et al. Among authors: patterson lh. Anticancer Drug Des. 1998 Sep;13(6):541-73. Anticancer Drug Des. 1998. PMID: 9755718 Review.

8

Molecular chemotherapy for breast cancer.

Patterson A, Harris AL. Patterson A, et al. Drugs Aging. 1999 Feb;14(2):75-90. doi: 10.2165/00002512-199914020-00001. Drugs Aging. 1999. PMID: 10084362 Review.

9

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

Chinje EC, Patterson AV, Saunders MP, Lockyer SD, Harris AL, Stratford IJ. Chinje EC, et al. Among authors: patterson av. Br J Cancer. 1999 Dec;81(7):1127-33. doi: 10.1038/sj.bjc.6690819. Br J Cancer. 1999. PMID: 10584872 Free PMC article.

10

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.

Saunders MP, Patterson AV, Chinje EC, Harris AL, Stratford IJ. Saunders MP, et al. Among authors: patterson av. Br J Cancer. 2000 Feb;82(3):651-6. doi: 10.1054/bjoc.1999.0977. Br J Cancer. 2000. PMID: 10682679 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

107 results

Search Page

Filters